Venoo, Krish

Venoo, Krish was paid $158K by Medicaid between Jan 2019 and Jan 2024, across 11 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 34% of everything it billed.

Compared with peers

Next to other Surgery Physician providers in Illinois

Rank by total paid#19 of 422

Median peer was paid$5K

This provider vs. median31×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2019	36	$2K
2022	913	$34K
2023	4,420	$111K
2024incomplete	196	$12K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	34%	998	471	$54K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	28%	1,157	632	$43K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	13%	1,117	514	$20K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	11%	985	494	$18K
87637	Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV	9.4%	215	104	$15K
36556		2.1%	68	54	$3K
99223	Prolong inpt eval add15 m	1.2%	29	23	$2K
99254		<1%	14	13	$929.60
87811	Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19)	<1%	16	15	$600.01
99211	Office or other outpatient visit for the evaluation and management of an established patient, minimal severity	<1%	950	458	$436.84
87804	Infectious agent antigen detection by immunoassay; Influenza, each type	<1%	16	15	$430.39

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.